Ovid Therapeutics (OVID) has shared an announcement.
Ovid Therapeutics Inc. has announced that Takeda Pharmaceutical Company Limited released the Phase 3 topline results for soticlestat. This significant development was shared with the public through a press release, which highlights the ongoing advancements in the company’s pharmaceutical endeavors. The release marks an important step in the regulatory process, although the information is not considered formally filed under securities law.
Learn more about OVID stock on TipRanks’ Stock Analysis page.
